Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Vacca

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 24, 2010
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibitionHemaka A Rajapakse, Philippe G Nantermet, Harold G Selnick, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2008
10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutantsCatherine M Wiscount, Peter D Williams, Lekhanh O Tran, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Journal of Medicinal Chemistry|May 28, 2004
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitorsMary Beth Young, James C Barrow, Kristen L Glass, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
A potent and orally active HIV-1 integrase inhibitorMelissa S Egbertson, H Marie Moritz, Jeffrey Y Melamed, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamidesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2008
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primatesSethu Sankaranarayanan, Marie A Holahan, Dennis Colussi, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|February 24, 2010
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibitionHemaka A Rajapakse, Philippe G Nantermet, Harold G Selnick, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2008
10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutantsCatherine M Wiscount, Peter D Williams, Lekhanh O Tran, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Journal of Medicinal Chemistry|May 28, 2004
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitorsMary Beth Young, James C Barrow, Kristen L Glass, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
A potent and orally active HIV-1 integrase inhibitorMelissa S Egbertson, H Marie Moritz, Jeffrey Y Melamed, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamidesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2008
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primatesSethu Sankaranarayanan, Marie A Holahan, Dennis Colussi, et al.
Pageof 9